FrancophonIA/ELRC3.0 huggingface dataset:
English: PREZISTA given with low dose ritonavir may be considered as an alternative.
Slovenian: Kot alternativno zdravljenje se lahko uporabi zdravilo PREZISTA z majhnim odmerkom ritonavirja.
English: Clinical monitoring is recommended when co-administering PREZISTA with low dose ritonavir with these analgesics.
Slovenian: Pri sočasni uporabi zdravila PREZISTA z majhnim odmerkom ritonavirja in teh analgetikov je priporočljivo klinično spremljanje bolnika.
English: PREZISTA/ ritonavir 800/100 mg once daily N=294
Slovenian: 800/100 mg enkrat na dan N=294
English: Boosted PREZISTA is expected to increase these antineoplastic plasma concentrations.
Slovenian: Pričakovati je, da okrepljeno zdravilo PREZISTA zviša plazemske koncentracije navedenih zaviralcev adrenergičnih receptorjev beta.
English: Systemic dexamethasone should be used with caution when combined with PREZISTA co-administered with low dose ritonavir.
Slovenian: Pri sočasni uporabi sistemsko danega deksametazona in zdravila PREZISTA ter ritonavirja v majhnem odmerku je potrebna previdnost.
English: Caution should be exercised when combining one of these antineoplastic agents with PREZISTA with low dose ritonavir.
Slovenian: Pri kombiniranju teh zdravil proti raku z zdravilom PREZISTA skupaj z majhnim odmerkom ritonavirja je potrebna previdnost.
English: An increase of systemic exposure to darunavir was observed when PREZISTA co-administered with 100 mg ritonavir was co-administered with rifabutin (150 mg once every other day).
Slovenian: Pri sočasni uporabi zdravila PREZISTA s 100 mg ritonavira in rifabutina (150 mg rifabutina enkrat vsak drugi dan) so opažali zvečanje sistemske izpostavljenosti darunavirju.
English: Exposure to these immunosuppressants will be increased when co-administered with boosted PREZISTA.
Slovenian: Pričakovano je zvečanje izpostavljenosti navedenim imunosupresivom pri njihovi sočasni uporabi z okrepljenim zdravilom PREZISTA (zaviranje CYP3A)
English: Dose adjustment for buprenorphine may not be necessary when co-administered with PREZISTA/ritonavir but a careful clinical monitoring for signs of opiate toxicity is recommended.
Slovenian: Pri sočasni uporabi zdravila PREZISTA z majhnim odmerkom ritonavirja in klonazepama je priporočljivo klinično spremljanje bolnika.
English: No adjustment of methadone dosage is required when initiating co-administration with PREZISTA/ritonavir.
Slovenian: Ob uvedbi sočasnega zdravljenja z zdravilom PREZISTA/ritonavir prilagajanje odmerka metadona ni potrebno.
English: Patients with no/non-naïve use of ENF
Slovenian: vsi razponi vsi razponi vsi bolniki bolniki, ki še niso/niso prvič jemali ENF bolniki, ki so prvič jemali ENF
English: excessive sweating, night sweats, hair loss, acne, scaly skin, colouration of nails - muscle pain, muscle cramps or weakness, pain in extremity, osteoporosis
Slovenian: včasih tudi ponoči - koprivnica, zelo otečena koža in druga tkiva (najpogosteje ustnic ali oči), ekcem, prekomerno potenje, nočno potenje, izguba las, akne, koža, ki se lušči, obarvanje nohtov - bolečina v mišicah, krči v mišicah, bolečine v okončinah, osteoporoza
English: The full EPAR for Riprazo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Riprazo je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This is a summary of the European public assessment report (EPAR) for Riprazo.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Riprazo.
English: The recommended dose of Riprazo is 150 mg once a day.
Slovenian: Priporočeni odmerek zdravila Riprazo je 150 mg enkrat dnevno.
English: What benefit has Riprazo shown during the studies?
Slovenian: Kakšne koristi je zdravilo Riprazo izkazalo med študijami?
English: Riprazo has been studied in 14 main studies involving over 10,000 patients with essential hypertension.
Slovenian: Zdravilo Riprazo so raziskali v 14 glavnih študijah, v katere je bilo vključenih več kot 10 000 bolnikov z esencialno hipertenzijo.
English: It is available as tablets (150 and
Slovenian: Na voljo je v obliki tablet (150 in 300 mg).
English: The CHMP therefore decided that the benefits of Riprazo are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: CHMP je zato zaključil, da so koristi zdravila Riprazo večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
English: It should be taken with a light meal preferably at the same time each day, but grapefruit juice should not be taken together with Riprazo.
Slovenian: Vzeti ga je treba z lahkim obrokom, najbolje vsak dan ob istem času, vendar pa se zdravilo Riprazo ne sme vzeti skupaj s sokom grenivke.
English: For more information about treatment with Riprazo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Riprazo preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
English: Riprazo is used to treat essential hypertension (high blood pressure) in adults.
Slovenian: Zdravilo Riprazo se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Riprazo, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: This may reduce the risks associated with high blood pressure, such as having a stroke.
Slovenian: S tem se lahko zmanjša tudi tveganje, povezano z visokim krvnim tlakom, kot je kap.
English: When the results of the five studies comparing Riprazo taken alone with placebo were looked at together, patients aged under 65 years had an average fall in diastolic blood pressure of 9.0 mmHg after eight weeks of taking 150 mg Riprazo, from an average of 99.4 mmHg at the start of the study.
Slovenian: Ko so primerjali rezultate vseh petih študij, v katerih so zdravilo Riprazo kot samostojno zdravilo primerjali s placebom, se je pri bolnikih, mlajših od 65 let, po osmih tednih jemanja 150 mg zdravila Riprazo povprečni diastolični tlak, ki je na začetku znašal 99,4 mmHg, v povprečju znižal za 9,0 mmHg.
English: What is the risk associated with Riprazo?
Slovenian: Kakšna tveganja so povezana z zdravilom Riprazo?
English: It must not be used in patients who have had angioedema (swelling under the skin) with aliskiren, hereditary angioedema or angioedema of no obvious cause, or in women who are more than three months pregnant.
Slovenian: Ne sme se uporabljati pri bolnikih, pri katerih se je zaradi jemanja aliskirena pojavil angioedem (podkožno otekanje), pri bolnikih z dednim angioedemom ali angioedemom brez jasnega vzroka ter pri ženskah, ki so noseče več kot tri mesece.
English: Riprazo is a medicine that contains the active substance aliskiren.
Slovenian: Riprazo je zdravilo, ki vsebuje zdravilno učinkovino aliskiren.
English: The studies with Riprazo in combination with other medicines showed additional decreases in blood pressure compared with the decreases produced by these medicines alone.
Slovenian: Študije z zdravilom Riprazo v kombinaciji z drugimi zdravili so pokazale dodatno znižanje krvnega tlaka v primerjavi z znižanjem, ki so ga ta zdravila dosegla samostojno.
English: Riprazo also reduced blood pressure in patients with diabetes and patients who were overweight.
Slovenian: Zdravilo Riprazo je krvni tlak znižalo tudi pri bolnikih s sladkorno boleznijo in tistih s prekomerno težo.
English: Why has Riprazo been approved?
Slovenian: Zakaj je bilo zdravilo Riprazo odobreno?
English: The CHMP noted that Riprazo is effective in reducing blood pressure when used alone or in combination.
Slovenian: CHMP je ugotovil, da je zdravilo Riprazo učinkovito pri zniževanju krvnega tlaka, kadar se uporablja samostojno ali v kombinaciji z drugim zdravilom.
English: Riprazo must also not be taken with ciclosporin, itraconazole or other medicines known as ‘potent P-glycoprotein inhibitors' (such as quinidine).
Slovenian: Riprazo se prav tako ne sme jemati skupaj s ciklosporinom, itrakonazolom ali drugimi zdravili, znanimi kot „močni zaviralci P-glikoproteina“ (kot je kinidin).
English: For the full list of all side effects reported with Riprazo, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Riprazo, glejte navodilo za uporabo.
English: The European Commission granted a marketing authorisation valid throughout the European Union for
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Riprazo, veljavno po vsej Evropski uniji, odobrila dne 22. avgusta 2007.
English: The most common side effects with Riprazo (seen in between 1 and 10 patients in 100) are dizziness, diarrhoea, arthralgia (joint pain) and hyperkalaemia (high blood potassium levels).
Slovenian: Najpogostejši neželeni učinki zdravila Riprazo (opaženi pri 1 do 10 bolnikih od 100) so omotica, driska, artralgija (bolečine v sklepih) in hiperkaliemija (visoke ravni kalija v krvi).
English: Riprazo must not be used by people who are hypersensitive (allergic) to aliskiren or any of the other ingredients.
Slovenian: Zdravila Riprazo ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) aliskiren ali katero koli drugo sestavino zdravila.
English: In five of the studies, the effects of Riprazo taken alone were compared with those of placebo (a dummy treatment).
Slovenian: V petih študijah so učinke jemanja zdravila Riprazo, uporabljenega kot samostojno zdravilo, primerjali s placebom (zdravilom brez zdravilne učinkovine).
English: However, in February 2012, following the review of a study called ALTITUDE, the CHMP recommended that Riprazo should not be used together with an ACE inhibitor or ARB in patients with diabetes or with moderate or severe kidney impairment because of an increase in the risk of cardiovascular and kidney problems.
Slovenian: Vendar pa je februarja 2012, po pregledu študije ALTITUDE, CHMP priporočil, da se zdravilo Riprazo ne uporablja skupaj z zaviralcem angiotenzinske konvertaze ali zaviralcem angiotenzinskih receptorjev pri bolnikih s sladkorno boleznijo oziroma zmerno ali hudo okvaro ledvic zaradi povišanega tveganja za srčnožilne težave in težave z ledvicami.
English: Riprazo, taken alone or in combination with other medicines, was also compared with other medicines for hypertension.
Slovenian: Zdravilo Riprazo so kot samostojno zdravilo ali v kombinaciji z drugimi zdravili primerjali tudi z drugimi zdravili za zdravljenje hipertenzije.
English: The active substance in Riprazo, aliskiren, is a renin inhibitor.
Slovenian: Zdravilna učinkovina zdravila Riprazo, aliskiren, spada med zaviralce renina.
English: Larger falls were seen in patients aged 65 years or over and those taking higher doses of Riprazo.
Slovenian: Pri bolnikih, starih 65 let ali več, in tistih, ki so jemali večje odmerke zdravila Riprazo, so opazili večje znižanje tlaka.
English: How does Riprazo work?
Slovenian: Kako zdravilo Riprazo deluje?
English: Riprazo on its own was more effective than placebo and as effective as comparator treatments in reducing blood pressure.
Slovenian: Zdravilo Riprazo kot samostojno zdravilo je bilo pri zdravljenju visokega krvnega tlaka učinkovitejše od placeba in enako učinkovito kot zdravljenje s primerljivimi zdravili.
English: Riprazo may be taken alone or in combination with other medicines for hypertension, with the exception of ‘angiotensin converting enzyme (ACE) inhibitors' or ‘angiotensin receptor blockers' (ARBs) in patients with diabetes, or moderate or severe kidney impairment.
Slovenian: Zdravilo Riprazo se lahko jemlje samostojno ali v kombinaciji z drugimi zdravili za zdravljenje hipertenzije z izjemo „zaviralcev angiotenzinske konvertaze (ACE)“ ali „zaviralcev angiotenzinskih receptorjev (ARB)“ pri bolnikih s sladkorno boleznijo oziroma zmerno ali hudo okvaro ledvic.
English: Combination studies looked at Riprazo used with an ACE inhibitor (ramipril), an ARB (valsartan), a beta-blocker (atenolol), a calcium-channel blocker (amlodipine) and a diuretic (hydrochlorothiazide).
Slovenian: V študijah kombinacij zdravil so zdravilo Riprazo proučevali v kombinaciji z zaviralcem angiotenzinske konvertaze (ramiprilom), zaviralcem angiotenzinskih receptorjev (valsartanom), zaviralcem receptorjev beta (atenololom), zaviralcem kalcijevih kanalčkov (amlodipinom) in diuretikom (hidroklorotiazidom).
English: This was compared with a fall of 5.8 mmHg from 99.3 mmHg in the patients
Slovenian: Rezultate so primerjali z znižanjem pri bolnikih, ki so jemali placebo, pri katerih se je diastolični tlak, ki je na začetku znašal 99,3 mmHg, znižal za 5,8 mmHg.
English: The dose of Riprazo may be increased to 300 mg once a day in patients whose blood pressure is not adequately controlled.
Slovenian: Pri bolnikih, pri katerih krvni tlak ni ustrezno uravnan, se lahko odmerek zdravila Riprazo poveča na 300 mg enkrat dnevno.
English: Riprazo in combination with an ACE inhibitor or an ARB must not be used in patients with diabetes, or moderate or severe kidney impairment.
Slovenian: Zdravilo Riprazo se v kombinaciji z zaviralcem angiotenzinske konvertaze ali zaviralcem angiotenzinskih receptorjev ne sme uporabljati pri bolnikih s sladkorno boleznijo oziroma zmerno ali hudo okvaro ledvic.
English: The European Commission granted a marketing authorisation valid throughout the EU for Tevagrastim to Teva Generics GmbH on 15 September 2008.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Tevagrastim, veljavno po vsej Evropski uniji, odobrila družbi Teva Generics GmbH dne 15. septembra 2008.
English: How it is given, the dose and the duration of treatment depend on why it is being used, the patient's body weight and the response to treatment.
Slovenian: Način dajanja, odmerek in trajanje zdravljenja so odvisni od namena uporabe, telesne mase bolnika in odziva na zdravljenje.
English: This means that Tevagrastim is similar to a biological medicine that is already authorised in the European Union (EU) and contains the same active substance (also known as the ‘reference medicine').
Slovenian: To pomeni, da je zdravilo Tevagrastim podobno biološkemu zdravilu, ki je že odobreno v Evropski uniji (EU) in vsebujejo enako zdravilno učinkovino (t.i. „referenčno zdravilo“).
English: Filgrastim is produced by a method known as ‘recombinant DNA technology': it is made by a bacterium that has received a gene (DNA), which makes it able to produce filgrastim.
Slovenian: Filgrastim se izdeluje z metodo, imenovano „tehnologija rekombinantne DNK“: proizvaja ga bakterija, ki je prejela gen (DNK), s pomočjo katerega postane sposobna tvoriti filgrastim.
English: During the first 21-day chemotherapy cycle, patients treated with either Tevagrastim or Neupogen had severe neutropenia for an average of 1.1 days, compared with 3.8 days in those receiving placebo.
Slovenian: Med prvim 21 dnevnim ciklom kemoterapije so imeli bolniki, zdravljeni bodisi z zdravilom Tevagrastim ali Neupogen, hudo netropenijo v povprečju 1,1 dan, v primerjavi s 3,8 dnevi pri tistih, ki so prejemali placebo.
English: The most common side effect with Tevagrastim (seen in more than 1 patient in 10) is musculoskeletal pain (pain in the muscles and bones).
Slovenian: Najpogostejši neželeni učinek zdravila Tevagrastim (opažen pri več kot 1 bolniku izmed 10) je mišičnoskeletna bolečina (bolečina v mišicah in kosteh).
English: To study the safety of Tevagrastim, two further studies were carried out in patients with lung cancer and with non-Hodgkin's lymphoma.
Slovenian: Za preučitev varnosti zdravila Tevagrastim sta bili izvedeni še dve študiji z bolniki s pljučnim rakom in z neHodgkinovim limfomom.
English: Other information about Tevagrastim:
Slovenian: Druge informacije o zdravilu Tevagrastim:
English: The active substance in Tevagrastim, filgrastim, is very similar to a human protein called granulocyte colony stimulating factor (G-CSF).
Slovenian: Učinkovina v zdravilu Tevagrastim, filgrastim, je zelo podobna človeški beljakovini, imenovani granulocitne kolonije stimulirajoči faktor (granulocyte colony stimulating factor - G-CSF).
English: Tevagrastim is used to stimulate the production of white blood cells in the following situations:
Slovenian: Zdravilo Tevagrastim se uporablja za spodbujanje tvorbe belih krvničk v naslednjih primerih:
English: The Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Tevagrastim has been shown to have a comparable quality, safety and efficacy profile to Neupogen.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da je bilo v skladu z zahtevami Evropske unije dokazano, da ima zdravilo Tevagrastim podoben profil kakovosti, varnosti in učinkovitosti kot zdravilo Neupogen.
English: Tevagrastim should not be used in people who may be hypersensitive (allergic) to filgrastim or any of the other ingredients.
Slovenian: Zdravila Rebetol se ne sme uporabljati pri ljudeh, ki utegnejo biti preobčutljivi za (alergični na) filgrastim ali katero koli drugo sestavino zdravila.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) TEVAGRASTIM EPAR summary for the public
Slovenian: EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) TEVAGRASTIM Povzetek EPAR za javnost
English: Other side effects may be seen in more than 1 patient in 10, depending on the condition that Tevagrastim is being used for.
Slovenian: Pri več kot 1 bolniku izmed 10 se lahko pojavijo tudi drugi neželeni učinki, v odvisnosti od stanja, zaradi katerega se zdravilo Tevagrastim uporablja.
English: Tevagrastim is usually given in a specialised treatment centre, although patients who receive it by injection under the skin may inject themselves once they have been trained appropriately.
Slovenian: Zdravilo Tevagrastim se običajno daje v specializiranem zdravstvenem centru, vendar pa si ga lahko bolniki, ki ga prejemajo s podkožno injekcijo, dajejo tudi sami, pod pogojem, da so bili ustrezno usposobljeni.
English: Tevagrastim can also be used in patients who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow.
Slovenian: Zdravilo Tevagrastim se lahko uporablja tudi pri bolnikih, ki bi naj darovali matične celice za presaditev, za sproščanje teh celic iz kostnega mozga.
English: The Committee recommended that Tevagrastim be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Tevagrastim odobri dovoljenje za promet.
English: The study looked at the duration of severe neutropenia during the patients' first cycle of cytotoxic chemotherapy.
Slovenian: Študija je preučevala trajanje hude nevtropenije med prvim ciklom citotoksične kemoterapije, ki ga je prejel bolnik.
English: Tevagrastim was compared to Neupogen and to placebo (a dummy treatment) in one main study involving 348 patients with breast cancer.
Slovenian: Zdravilo Tevagrastim so primerjali z zdravilom Neupogen in placebom v eni glavni študiji, ki je vključevala 348 bolnikov z rakom dojke.
English: What benefit has Tevagrastim shown during the studies?
Slovenian: Kakšne koristi je zdravilo Tevagrastim izkazalo med študijami?
English: Treatment with Tevagrastim and Neupogen brought about similar reductions in duration of severe neutropenia.
Slovenian: Zdravljenje z zdraviloma Tevagrastim in Neupogen je privedlo do podobnega skrajšanja trajanja hude nevtropenije.
English: Tevagrastim is given by injection under the skin or infusion into a vein.
Slovenian: Zdravilo Cepivo Tevagrastim se daje z injekcijo pod kožo ali infuzijo v veno.
English: The replacement acts in same way as naturally produced G-CSF by encouraging the bone marrow to produce more white blood cells.
Slovenian: Nadomestek deluje na enak način kot naravni granulocitne kolonije stimulirajoči faktor, in sicer tako, da spodbudi kostni mozeg, da tvori več belih krvničk.
English: • to increase levels of neutrophils and reduce the risk of infections in patients with neutropenia who have a history of severe, repeated infections;
Slovenian: • za povečanje števila nevtrofilcev in zmanjšanje tveganja za okužbe pri bolnikih z nevtropenijo, ki so imeli v preteklosti hujše, ponavljajoče se okužbe;
English: What is the risk associated with Tevagrastim?
Slovenian: Kakšna tveganja so povezana z zdravilom Tevagrastim?
English: For the full list of all side effects reported with Tevagrastim, see the Package Leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Tevagrastim, glejte navodilo za uporabo.
English: Tevagrastim is a solution for injection or for infusion (drip into a vein).
Slovenian: Zdravilo Tevagrastim je raztopina za injiciranje ali infundiranje (dajanje v veno).
English: • to reduce the duration of neutropenia in patients undergoing treatment to destroy the bone marrow cells before a bone marrow transplant (such as in some patients with leukaemia) if they are at a risk of long-term, severe neutropenia;
Slovenian: • za skrajšanje trajanja nevtropenije pri bolnikih, ki se zdravijo s terapijo, katere cilj je uničenje celic kostnega mozga pred presaditvijo kostnega mozga (kot npr. pri bolnikih z levkemijo), pri katerih obstaja tveganje za dlje trajajočo hudo nevtropenijo;
English: • to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving chemotherapy
Slovenian: • za skrajšanje trajanja nevtropenije (nizke ravni nevtrofilcev, vrste belih krvničk) in zmanjšanje pojava febrilne nevtropenije (nevtropenije s povišano telesno temperaturo) pri bolnikih, ki prejemajo kemoterapijo (zdravljenje proti raku), ki je citotoksična (ubija celice);
English: infection, to reduce the risk of bacterial infections when other treatments are not appropriate.
Slovenian: • za zdravljenje netropenije pri bolnikih z napredovalo okužbo z virusom humane imunske pomanjkljivosti (HIV), z namenom zmanjšanja tveganja za bakterijske okužbe, ko druge oblike zdravljenja niso primerne.
English: Therefore, the CHMP's view was that, as for Neupogen, the benefit outweighs the identified risk.
Slovenian: Zaradi tega je CHMP menil, da so koristi zdravila Tevagrastim, tako kot pri zdravilu Neupogen, večje od znanih tveganj.
English: Therefore, the effectiveness of Tevagrastim was shown to be equivalent to that of Neupogen.
Slovenian: Tako je bilo dokazano, da je učinkovitost zdravila Tevagrastim ekvivalentna učinkovitosti zdravila Neupogen.
English: Why has Tevagrastim been approved?
Slovenian: Zakaj je bilo zdravilo Tevagrastim odobreno?
English: Tevagrastim was studied to show that it is comparable to the reference medicine, Neupogen.
Slovenian: Zdravilo Tevagrastim so preučevali, da bi dokazali, da je podobno referenčnemu zdravilu Neupogen.
English: The reference medicine for Tevagrastim is Neupogen.
Slovenian: Referenčno zdravilo za zdravilo Tevagrastim je zdravilo Neupogen.
English: Tevagrastim is a ‘biosimilar' medicine.
Slovenian: Zdravilo Tevagrastim je podobno biološko zdravilo.
English: What is Tevagrastim?
Slovenian: Kaj je zdravilo Tevagrastim?
English: How has Tevagrastim been studied?
Slovenian: Kako je bilo zdravilo Tevagrastim raziskano?
English: What is Tevagrastim used for?
Slovenian: Za kaj se zdravilo Tevagrastim uporablja?
English: The full EPAR for Tevagrastim can be found here.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Tevagrastim je na voljo tukaj.
English: How is Tevagrastim used?
Slovenian: Kako se zdravilo Tevagrastim uporablja?
English: How does Tevagrastim work?
Slovenian: Kako zdravilo Tevagrastim deluje?
English: A main measure of effectiveness was a reduction of at least 90% in PASI scores.
Slovenian: Glavno merilo učinkovitosti je bilo znižanje ocene PASI za vsaj 90 %.